N17
Conditions
Interventions
Group 1: Continuous veno-venous hemofiltration with HF-Citrate 39-210T and regional citrate anticoagulation
Group 2: Continuous veno-venous hemofiltration with MultiBic 2mmol/L Kalium and systemic hep
Sponsors
Fresenius Medical Care Deutschland GmbH
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Written informed consent given, Adult patients >18 years, Diagnosis of acute renal failure and indication for renal replacement therapy as assessed by volume overload, not correctable by diuretics in spite of adequate blood pressure and creatinine > 1.2 mg/dl, or increase of serum creatinine > 2.5 mg/dl or BUN > 50 mg/dl, or increase of serum potassium > 5.5 mmol/l due to oligo-anuria, Patients which at the time of inclusion have not yet started with the renal replacement therapy, Arterial line as vascular access, Mechanical ventilation
Exclusion criteria
Exclusion criteria: HIT II (heparin-induced thrombocytopenia type 2), Need to continue effective systemic heparin anticoagulation with an aPTT > 20% above the upper limit of the normal range , Metabolic alkalosis as defined by a pH > 7.50 and base excess of > +4 mmol/L, Pregnancy, lactation period, Patient on chronic renal replacement therapy, Participation in another study during the preceding 3 months, Previous participation in the same study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Acid-base status on day three after initiation of the CVVH treatment and on each consecutive day. | — |
Secondary
| Measure | Time frame |
|---|---|
| Therapeutic safety of the citrate based HF solution in comparison to bicarbonate HF solution with particular focus on adverse events like bleeding complications, heparin induced thrombocytopenia and mortality, acid-base derangements and systemic ionised calcium levels. | — |
Countries
Germany
Contacts
Public ContactAdelheid Gauly
Fresenius Medical Care Deutschland GmbH
Outcome results
None listed